

Online resource 4 – Multivariate analyses with adjuvant treatment and WHO grade.

**Title**

**IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas**

Acta Neuropathologica

**Authors:** Adriana Olar, Khalida M. Wani, Kristin Diefes, Lindsey E. Heathcock, Hinke F. van Thuijl, Mark R. Gilbert, Terri S. Armstrong, Erik P. Sulman, Daniel P. Cahill, Elizabeth Vera-Bolanos, Ying Yuan, Jaap C. Reijneveld, Bauke Ylstra, Pieter Wesseling, Kenneth D. Aldape

**Corresponding authors:**

Adriana Olar, MD  
The University of Texas MD Anderson Cancer Center  
Dept. of Pathology, G1.3510  
1515 Holcombe Blvd.  
Houston, TX, 77030, USA  
Email: [adriana\\_olar@yahoo.com](mailto:adriana_olar@yahoo.com)

Kenneth Aldape, MD  
Princess Margaret Cancer Centre and Ontario Cancer Institute  
610 University Ave  
Toronto, ON M5G 2M9, Canada  
Email: [ken.aldaape@uhnresearch.ca](mailto:ken.aldaape@uhnresearch.ca)

**Table S4.1:** Cox multivariate analysis among all 439 diffuse glioma cases on which adjuvant treatment data were available; with mitotic index (A) and with WHO grade (B).

**A**

Variable	p-value	Hazard Ratio	95% CI
<b>IDH status (mut vs wt)</b>	<0.0001	0.36	0.25-0.52
<b>1p/19q status (codel vs non-codel)</b>	<0.0009	0.57	0.40-0.79
<b>Mitotic index (high vs low)</b>	<0.0001	2.00	1.49-2.68
<b>Age</b>	<0.0001	1.03	1.02-1.04
<b>Adjuvant chemotherapy (yes vs. no)</b>	0.1900	0.82	0.61-1.10
<b>Adjuvant radiation (yes vs. no)</b>	0.0020	0.58	0.41-0.82

**B**

Variable	p-value	Hazard Ratio	95% CI
<b>IDH status (mut vs. wt)</b>	<0.0001	0.34	0.24-0.49
<b>1p/19q status (codel vs. non-codel)</b>	<0.0060	0.63	0.45-0.88
<b>WHO grade (III vs. II)</b>	0.1388	1.28	0.92-1.77
<b>Age</b>	<0.0001	1.03	1.02-1.04
<b>Adjuvant chemotherapy (yes vs. no)</b>	0.0956	0.78	0.58-1.05
<b>Adjuvant radiation (yes vs. no)</b>	0.0179	0.65	0.45-0.93

CI: confidence interval, codel – co-deleted, mut – mutant, wt – wild-type.

**Table S4.2:** Cox multivariate analysis on 373 IDH-mutant cases on which adjuvant treatment data were available; with mitotic index (A) and with WHO grade (B).

A	Variable	p-value	Hazard Ratio	95% CI
	<b>1p/19q status (codel vs. non-codel)</b>	0.0052	0.62	0.44-0.87
	<b>Mitotic index (high vs. low)</b>	0.0566	1.41	0.99-2.02
	<b>Age</b>	0.3229	1.01	0.99-1.02
	<b>Adjuvant chemotherapy (yes vs. no)</b>	0.2433	0.82	0.59-1.14
	<b>Adjuvant radiation (yes vs. no)</b>	0.0028	0.55	0.37-0.81

B	Variable	p-value	Hazard Ratio	95% CI
	<b>1p/19q status (codel vs. non-codel)</b>	0.0098	0.64	0.46-0.90
	<b>WHO grade (III vs. II)</b>	0.4804	1.14	0.79-1.64
	<b>Age</b>	0.3696	1.01	0.99-1.02
	<b>Adjuvant chemotherapy (yes vs. no)</b>	0.1424	0.78	0.56-1.09
	<b>Adjuvant radiation (yes vs. no)</b>	0.0140	0.59	0.39-0.90

CI: confidence interval, codel – co-deleted, mut – mutant, wt – wild-type.

**Table S4.3:** Cox multivariate analysis on 66 IDH-wild type cases on which adjuvant treatment data were available; with mitotic index (A) and with WHO grade (B).

**A**

Variable	p-value	Hazard Ratio	95% CI
<b>Mitotic index (high vs. low)</b>	0.0015	3.10	1.54-6.24
<b>Age</b>	<0.0001	1.04	1.02-1.06
<b>Adjuvant chemotherapy (yes vs. no)</b>	0.8990	0.95	0.44-2.06
<b>Adjuvant radiation (yes vs. no)</b>	0.8367	0.92	0.41-2.05

**B**

Variable	p-value	Hazard Ratio	95% CI
<b>WHO grade (III vs. II)</b>	0.0363	2.25	1.05-4.79
<b>Age</b>	<0.0001	1.06	1.04-1.08
<b>Adjuvant chemotherapy (yes vs. no)</b>	0.8539	0.93)	(0.44-1.99)
<b>Adjuvant radiation (yes vs. no)</b>	0.6839	0.85	0.38-1.89

CI: confidence interval.